Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1533"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label |
"evidence_1430"
|
| ?:Evidence_type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_value | |
| dc:creator | |
| dc:date |
"09/01/2010 14:06:24"
|
| ?:content |
"NOTE: AUC_i/AUC is AUC_0-24.
route of administration: oral
study duration: 6 days
population: 12 healthy volunteers (all male), all Japanese
tested for known CYP450 polymorphisms? No
ages: 20-28
description: Twelve healthy Japanese male volunteers were enrolled in this study. Their mean age (+/- SD) was 24.0 +/- 2.0 years (range, 20-28 years), and their mean body weight was 64.8 +/- 6.2 kg (range, 53-86 kg).
METHODS: A randomized crossover study design was conducted at intervals of 4 weeks. Two 40-mg tablets of verapamil (Vasolan; Eisai Pharmaceutical, Tokyo, Japan) 3 times daily (at 8 AM, 1 PM, and 6 PM) or matched placebo with 240 mL of tap water was given for 6 days. The volunteers took a single oral 1-mg dose of risperidone at 9 AM on day 6 with 240 mL of tap water.
RESULTS: The total AUC of risperidone during verapamil treatment was higher than during placebo by 1.82-fold (95% CI, 1.24- to 2.82-fold)."
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ verapamil_increases_auc_risperidone, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1430 }